Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.

Cholinergic Antagonists: Pharmacokinetics

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evidence-Based Consensus Guidelines Series for MicroPulse Transscleral Laser Therapy - Surgical Technique, Post-Operative Care, Expected Outcomes and Retreatment/Enhancements.

Clinical ophthalmology (Auckland, N.Z.)·2023

Same author

Evidence-Based Consensus Guidelines Series for MicroPulse Transscleral Laser Therapy: Dosimetry and Patient Selection.

Clinical ophthalmology (Auckland, N.Z.)·2022

Same author

Letter to the Editor: One-Year Outcomes of Micropulse Cyclophototherapy for Primary Open-angle Glaucoma.

Journal of glaucoma·2022

Same author

Histopathologic changes in cadaver eyes after MicroPulse and continuous wave transscleral cyclophotocoagulation.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2020

Same author

An Unusual Complication of Ocular Trauma in a 10-Year-Old Girl.

JAMA ophthalmology·2018

Same author

Selective Laser Trabeculoplasty as Primary Treatment for Open-Angle Glaucoma.

Rhode Island medical journal (2013)·2016

Search research articles

Related Experiment Video

Updated: May 30, 2026

Intracameral Injection in Rats with Low Risk of Adverse Effects

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Benzalkonium chloride in glaucoma medications.

Robert Noecker¹, Kimberly V Miller

¹Ophthalmic Consultants of Connecticut, Fairfield, CT 06824, USA. robertnoecker@comcast.net

The Ocular Surface

|July 28, 2011

Summary

Benzalkonium chloride (BAK) eye drops can harm ocular surface cells, especially with long-term use for conditions like glaucoma. Newer preservative-free options offer a safer alternative for patients requiring chronic eye drop therapy.

Area of Science:

Ophthalmology
Toxicology
Cell Biology

Background:

Benzalkonium chloride (BAK) is a widely used preservative in ophthalmic solutions.
BAK exhibits antimicrobial and antifungal properties.
Concerns exist regarding BAK's potential toxicity to ocular surface cells.

Purpose of the Study:

To review the adverse effects of Benzalkonium chloride (BAK) on ocular surface epithelial cells.
To highlight the implications of these effects for long-term topical ophthalmic medication use.
To discuss the emergence and availability of non-BAK-containing eye drops as alternatives.

Main Methods:

Review of in vitro and in vivo studies examining BAK's effects on ocular surface cells.
Analysis of clinical relevance for chronic ophthalmic conditions.

More Related Videos

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Related Experiment Videos

Last Updated: May 30, 2026

Intracameral Injection in Rats with Low Risk of Adverse Effects

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Evaluation of alternative preservative systems in eye drops.

Main Results:

Studies indicate that Benzalkonium chloride (BAK) can negatively impact surface epithelial cell populations in the eye.
These adverse effects are particularly relevant for patients using eye drops long-term, such as for glaucoma management.
The availability of newer eye drops without BAK is increasing.

Conclusions:

Benzalkonium chloride (BAK), despite its preservative efficacy, poses risks to ocular surface health.
Long-term exposure to BAK in eye drops warrants careful consideration due to potential cellular damage.
Alternative preservative-free formulations are crucial for patients requiring sustained ophthalmic treatment.